...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Shareholder Value

Much appreciated, Nextblockbuster!  I too have picked up shares on the OTC. Albeit somewhat nervously. ;)

Share
New Message
Please login to post a reply